Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristine B Patterson

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Antiviral Therapy|August 12, 2015
Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week resultsMichelle A Floris-Moore, Katie Mollan, Aimee M Wilkin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 1, 2012
Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?Jessica L Adams, Craig Sykes, Prema Menezes, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 16, 2014
Immunologic, virologic, and pharmacologic characterization of the female upper genital tract in HIV-infected womenLisa Rahangdale, Kristina De Paris, Angela D M Kashuba, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 16, 2014
Models for predicting effective HIV chemoprevention in womenMelanie R Nicol, Cindi W Emerson, Heather M A Prince, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 5, 2010
Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200Michael F Para, Jeff Schouten, Susan L Rosenkranz, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 28, 2006
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteersRosa F Yeh, Vincent E Gaver, Kristine B Patterson, et al.
AIDS (London, England)|August 28, 2007
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxisJulie B Dumond, Rosa F Yeh, Kristine B Patterson, et al.
The Journal of Infectious Diseases|April 20, 2011
Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative menKevin C Brown, Kristine B Patterson, Stephanie A Malone, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 17, 2008
The pharmacokinetics and viral activity of tenofovir in the male genital tractManoli Vourvahis, Hiba L Tappouni, Kristine B Patterson, et al.
Antimicrobial Agents and Chemotherapy|March 25, 2009
Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected womenRosa F Yeh, Naser L Rezk, Angela D M Kashuba, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Antiviral Therapy|August 12, 2015
Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week resultsMichelle A Floris-Moore, Katie Mollan, Aimee M Wilkin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 1, 2012
Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?Jessica L Adams, Craig Sykes, Prema Menezes, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 16, 2014
Immunologic, virologic, and pharmacologic characterization of the female upper genital tract in HIV-infected womenLisa Rahangdale, Kristina De Paris, Angela D M Kashuba, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 16, 2014
Models for predicting effective HIV chemoprevention in womenMelanie R Nicol, Cindi W Emerson, Heather M A Prince, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 5, 2010
Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200Michael F Para, Jeff Schouten, Susan L Rosenkranz, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 28, 2006
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteersRosa F Yeh, Vincent E Gaver, Kristine B Patterson, et al.
AIDS (London, England)|August 28, 2007
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxisJulie B Dumond, Rosa F Yeh, Kristine B Patterson, et al.
The Journal of Infectious Diseases|April 20, 2011
Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative menKevin C Brown, Kristine B Patterson, Stephanie A Malone, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 17, 2008
The pharmacokinetics and viral activity of tenofovir in the male genital tractManoli Vourvahis, Hiba L Tappouni, Kristine B Patterson, et al.
Antimicrobial Agents and Chemotherapy|March 25, 2009
Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected womenRosa F Yeh, Naser L Rezk, Angela D M Kashuba, et al.
Pageof 4